A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Public ClinicalTrials.gov record NCT05001282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.
Study identification
- NCT ID
- NCT05001282
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Conditions
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Endometrial Cancer
- Ovary Cancer
- Ovary Neoplasm
- Ovary Disease
- Ovary Metastasis
- Ovarian Diseases
- Ovarian Cancer Stage
- Ovarian Epithelial Cancer
- Ovarian Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Neoplasm Epithelial
- Ovarian Cancer Recurrent
- Endometrial Diseases
- Endometrial Adenocarcinoma
- Endometrial Carcinosarcoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrioid Adenocarcinoma
- Endometrial Neoplasms
- Endometrial Cancer Recurrent
- Endometrioid Tumor
- Fallopian Tube Cancer
- Peritoneal Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2021 (Actual)
- Primary completion
- Jun 7, 2024 (Actual)
- Completion
- Jun 7, 2024 (Actual)
- Last update posted
- Aug 7, 2024
2021 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Phoenix, AZ | Phoenix | Arizona | 85054 | — |
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| Mayo Clinic - Jacksonville, FL | Jacksonville | Florida | 32224 | — |
| D&H Cancer Research Center | Margate | Florida | 33063 | — |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Hope and Healing Cancer Services | Hinsdale | Illinois | 60521 | — |
| OSF Saint Francis Medical Center | Peoria | Illinois | 61606 | — |
| Mayo Clinic - Rochester, MN | Rochester | Minnesota | 55905 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center - Duke Cancer Institute | Durham | North Carolina | 27719 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Women & Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Sarah Cannon Research Institute at Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| New Experimental Therapeutics of San Antonio (NEXT Oncology) | San Antonio | Texas | 78229 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05001282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05001282 live on ClinicalTrials.gov.